Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients

The immunogenicity of the novel mRNA COVID-19 vaccine in immunocompromised lung transplant recipients is still unknown. We compared the antibody response after the first and second doses of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) with the response after natural SARS-CoV-2 infection in l...

Descripción completa

Detalles Bibliográficos
Autores principales: Havlin, Jan, Svorcova, Monika, Dvorackova, Eliska, Lastovicka, Jan, Lischke, Robert, Kalina, Tomas, Hubacek, Petr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society for Heart and Lung Transplantation. 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139179/
https://www.ncbi.nlm.nih.gov/pubmed/34120839
http://dx.doi.org/10.1016/j.healun.2021.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139179/
https://www.ncbi.nlm.nih.gov/pubmed/34120839
http://dx.doi.org/10.1016/j.healun.2021.05.004

Ejemplares similares